Effectiveness of chromium in atypical depression: A placebo-controlled trial

Biological Psychiatry

Volumn 53, Issue 3, 2003, Pages 261-264

  Davidson, Jonathan R T ^a   Abraham, Kurian ^a   Connor, Kathryn M ^a   McLeod, Malcolm N ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical depression; Chromium picolinate

Indexed keywords

CHROMIUM PICOLINATE; INSULIN; PLACEBO; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; ATYPICAL DEPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; INSULIN SENSITIVITY; MAJOR DEPRESSION; MALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037304640     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01500-7     Document Type: Article

References (28)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;American Psychiatric Association, Washington, DC.
2. Anderson R.A. Chromium, glucose intolerance and diabetes. J Am Coll Nutrition. 17:1998;548-555.
3. Anderson R.A., Polansky M.M., Bryden N.A., Bhathena S.J., Canary J. Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism. 36:1987;351-355.
4. 2A receptors. Psychopharmacology. 159:2002;432-436.
5. Barnett S.D., Tharwani H.M., Hertzberg M.A., Sutherland S.M., Connor K.M., Davidson J.R.T. Tolerability of fluoxetine in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 26:2001;363-367.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed:1988;Lawrence Erlbaum and Associates, Hillsdale, NJ.
7. Connor K.M., Davidson J.R.T., Churchill E. Adverse effect profile of kava. CNS Spectrums. 6:2001;848-853.
8. Davidson J.R.T., Giller E.L., Zisook S., Overall J.E. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry. 45:1988;120-127.
9. Davidson J.R.T., Miller R.D., Turnbull C.D., Sullivan J.L. Atypical depression. Arch Gen Psychiatry. 39:1982;527-534.
10. Davidson J.R.T., Woodbury M.A., Zisook S., Giller E.L. Classification of depression by grade of membership A continuation study . Psychol Med. 19:1989;987-998.
11. Davis C.M., Vincent J.B. Chromium oligopeptide activates insulin receptor kinase activity. Biochemistry. 36:1997;4382-4385.
12. Derogatis L.R., Lipman R.S., Covi L. SCL-90 An outpatient psychiatric rating scale - preliminary report . Psychopharmacol Bull. 9:1973;13-28.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;Department of Health and Human Services, Publication ADM, Washington, DC.
14. Hamilton M. The effect of treatment on the melancholias (depressions). Br J Psychiatry. 140:1982;223-230. 76-338.
15. Horacek J., Kuzmiakova M., Hoschl C., Andel M., Bahbonh R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology. 24:1999;785-787.
16. Jarrett R.B., Schaffer M., McIntire D., Witt-Browder A., Kraft D., Risser R.C. Treatment of atypical depression with cognitive therapy or phenelzine. Arch Gen Psychiatry. 56:1999;431-437.
17. McCarthy M.F. Enhancing central and peripheral insulin activity as a strategy for treatment of endogenous depression - an adjuvant role for chromium picolinate. Med Hypotheses. 43:1994;247-252.
18. McGrath P.J., Stewart J.W., Quitkin F.M., Wager S., Jenkins S.W., Archibald D.G., et al. Gepirone treatment of atypical depression Preliminary evidence of serotonergic involvement . J Clin Psychopharmcol. 14:1994;347-352.
19. McLeod M.N., Gaynes B.N., Golden R.N. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in five patients. J Clin Psychiatry. 60:1999;237-240.
20. McLeod M.N., Golden R.N. Chromium treatment of depression. Int J Neuropsychopharmacol. 3:2000;311-314.
21. Pande A.C., Birkett M., Fechner-Bates S., Haskett R.F., Greden J.F. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry. 40:1996;1017-1020.
22. Paykel E.S. Classification of depressed patients A cluster analysis derived grouping . Br J Psychiatry. 118:1972;275-288.
23. Paykel E.S., Mueller P.S., de la Vergne P.M. Amitriptyline, weight gain and carbohydrate craving A side effect . Br J Psychiatry. 123:1973;501-508.
24. Posternak M.A., Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry. 59:2002;70-76.
25. Quitkin F.M., Stewart J.W., McGrath P.J., Tricamo E., Rabkin J.G., Ocepek-Welikson I.K., et al. Columbia atypical depres-sion A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo . Br J Psychiatry. 163:(suppl 21):1993;30-34.
26. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (MINI) The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 . J Clin Psychiatry. 59:(suppl 20):1998;22-33.
27. Stewart J.W., McGrath P.J., Rabkin J.G., Quitkin F.M. Atypical depression. A valid clinical entity? Psychiatric Clin North Am. 16:1993;479-495.
28. Thase M., Fava M., Halbreich U., Kocsis J.H., Koran L., Davidson J.R.T., Rosenbaum J., Harrison W. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 53:1996;777-784.